Xanthohumol impairs human prostate cancer cell growth and invasion and diminishes the incidence and progression of advanced tumors in TRAMP mice

Molecular Medicine

Volumn 18, Issue 9, 2012, Pages 1292-1302

  Venè, Roberta ^a   Benelli, Roberto ^a   Minghelli, Simona ^b   Astigiano, Simonetta ^a   Tosetti, Francesca ^a   Ferrari, Nicoletta ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b G GASLINI INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

FOCAL ADHESION KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; XANTHOHUMOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL MOTILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ENZYME REGULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MIGRATION INHIBITION; MITOSIS INHIBITION; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA;

ADMINISTRATION, ORAL; ANDROGENS; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; FLAVONOIDS; G0 PHASE; G1 PHASE; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROPIOPHENONES; PROSTATIC NEOPLASMS; REACTIVE OXYGEN SPECIES;

EID: 84870317178     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/molmed.2012.00174     Document Type: Article

References (52)

1. Jemal A, et al. (2007) Cancer statistics, 2007. CA Cancer J. Clin. 57:43-66.
2. Debruyne F. (2002) Hormonal therapy of prostate cancer. Seminars in Urologic Oncology. 20:4-9.
3. Liang J, Slingerland JM. (2003) Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle. 2:339-45.
4. Bertram J, et al. (2006) Loss of PTEN is associated with progression to androgen independence. Prostate. 66:895-902.
5. Corson TW, Crews CM. (2007) Molecular understanding and modern application of traditional medicines: triumphs and trials. Cell. 130:769-74.
6. Gerhauser C, et al. (2002) Cancer chemopreventive activity of Xanthohumol, a natural product derived from hop. Mol. Cancer Ther. 1:959-69.
7. Lust S, et al. (2005) Xanthohumol kills B-chronic lymphocytic leukemia cells by an apoptotic mechanism. Mol. Nutr. Food Res. 49:844-50.
8. Vanhoecke B, et al. (2005) Antiinvasive effect of xanthohumol, a prenylated chalcone present in hops (Humulus lupulus L.) and beer. Int. J. Cancer. 117:889-95.
9. Pan L, Becker H, Gerhauser C. (2005) Xanthohumol induces apoptosis in cultured 40-16 human colon cancer cells by activation of the death receptor-and mitochondrial pathway. Mol. Nutr. Food Res. 49:837-43.
10. Delmulle L, Vanden Berghe T, Keukeleire DD, Vandenabeele P. (2008) Treatment of PC-3 and DU145 prostate cancer cells by prenylflavonoids from hop (Humulus lupulus L.) induces a caspaseindependent form of cell death. Phytother. Res. 22:197-203.
11. Albini A, et al. (2006) Mechanisms of the antiangiogenic activity by the hop flavonoid xanthohumol: NF-kappaB and Akt as targets. FASEB J. 20:527-9.
12. Colgate EC, Miranda CL, Stevens JF, Bray TM, Ho E. (2007) Xanthohumol, a prenylflavonoid derived from hops induces apoptosis and inhibits NF-kappaB activation in prostate epithelial cells. Cancer Lett. 246:201-9.
13. Lee SH, Kim HJ, Lee JS, Lee IS, Kang BY. (2007) Inhibition of topoisomerase I activity and efflux drug transporters' expression by xanthohumol from hops. Arch. Pharm. Res. 30:1435-9.
14. Zhao F, Nozawa H, Daikonnya A, Kondo K, Kitanaka S. (2003) Inhibitors of nitric oxide production from hops (Humulus lupulus L.). Biol. Pharm. Bull. 26:61-5.
15. Dell'Eva R, et al. (2007) AKT/NF-kappaB inhibitor xanthohumol targets cell growth and angiogenesis in hematologic malignancies. Cancer. 110:2007-11.
16. Monteghirfo S, et al. (2008) Antileukemia effects of xanthohumol in Bcr/Abl-transformed cells involve nuclear factor-kappaB and p53 modulation. Mol. Cancer Ther. 7:2692-702.
17. Benelli R, Monteghirfo S, Vene R, Tosetti F, Ferrari N. (2010) The chemopreventive retinoid 4HPR impairs prostate cancer cell migration and invasion by interfering with FAK/AKT/GSK3beta pathway and beta-catenin stability. Mol. Cancer. 9:142.
18. Committee for the Update of the Guide for the Care and Use of Laboratory Animals, Institute for Laboratory Animal Research, Division on Earth and Life Studies, National Research Council of the National Academies. (2011) Guide for the Care and Use of Laboratory Animals. 8th edition. Washington (DC): National Academies Press. [cited 2011 Sep 1]. Available from: http://oacu.od.nih.gov/regs/
19. Greenberg NM, et al. (1995) Prostate cancer in a transgenic mouse. Proc. Natl. Acad. Sci. U. S. A. 92:3439-43.
20. Kaplan-Lefko PJ, et al. (2003) Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model. Prostate. 55:219-37.
21. Larghero P, et al. (2007) Biological assays and genomic analysis reveal lipoic acid modulation of endothelial cell behavior and gene expression. Carcinogenesis. 28:1008-20.
22. Deeb D, et al. (2010) Growth inhibitory and apoptosis-inducing effects of xanthohumol, a prenylated chalone present in hops, in human prostate cancer cells. Anticancer Res. 30:3333-9.
23. Pang X, et al. (2011) 1(-Acetoxychavicol acetate suppresses angiogenesis-mediated human prostate tumor growth by targeting VEGFmediated Src-FAK-Rho GTPase-signaling pathway. Carcinogenesis. 32:904-12.
24. Sonoda Y, Watanabe S, Matsumoto Y, Aizu-Yokota E, Kasahara T. (1999) FAK is the upstream signal protein of the phosphatidylinositol 3-kinase-Akt survival pathway in hydrogen peroxide-induced apoptosis of a human glioblastoma cell line. J. Biol. Chem. 274:10566-70.
25. Shukla S, et al. (2007) Activation of PI3K-Akt signaling pathway promotes prostate cancer cell invasion. Int. J. Cancer. 121:1424-32.
26. Sachdev D, Yee D. (2007) Disrupting insulin-like growth factor signaling as a potential cancer therapy. Mol. Cancer Ther. 6:1-12.
27. Amit S, Ben-Neriah Y. (2003) NF-kappaB activation in cancer: a challenge for ubiquitination-and proteasome-based therapeutic approach. Semin. Cancer Biol. 13:15-28.
28. Aggarwal BB. (2004) Nuclear factor-kappaB: the enemy within. Cancer Cell. 6:203-8.
29. Lau AT, Wang Y, Chiu JF. (2008) Reactive oxygen species: current knowledge and applications in cancer research and therapeutic. J. Cell. Biochem. 104:657-67.
30. Strathmann J, et al. (2010) Xanthohumol-induced transient superoxide anion radical formation triggers cancer cells into apoptosis via a mitochondriamediated mechanism. FASEB J. 24:2938-50.
31. Albini A, et al. (2001) Inhibition of angiogenesisdriven Kaposi's sarcoma tumor growth in nude mice by oral N-acetylcysteine. Cancer Res. 61:8171-8.
32. Bubici C, Papa S, Dean K, Franzoso G. (2006) Mutual cross-talk between reactive oxygen species and nuclear factor-kappa B: molecular basis and biological significance. Oncogene. 25:6731-48.
33. Gingrich JR, et al. (1997) Androgen-independent prostate cancer progression in the TRAMP model. Cancer Res. 57:4687-91.
34. Klein RD, Kant JA. (2006) Opportunity knocks: the pathologist as laboratory genetics consultant. Arch. Pathol. Lab. Med. 130:1603-4.
35. Gupta S, Hastak K, Ahmad N, Lewin JS, Mukhtar H. (2001) Inhibition of prostate carcinogenesis in TRAMP mice by oral infusion of green tea polyphenols. Proc. Natl. Acad. Sci. U. S. A. 98:10350-5.
36. Raina K, Singh RP, Agarwal R, Agarwal C. (2007) Oral grape seed extract inhibits prostate tumor growth and progression in TRAMP mice. Cancer Res. 67:5976-82.
37. Singh SV, et al. (2009) Sulforaphane inhibits prostate carcinogenesis and pulmonary metastasis in TRAMP mice in association with increased cytotoxicity of natural killer cells. Cancer Res. 69:2117-25.
38. Pannellini T, et al. (2010) A dietary tomato supplement prevents prostate cancer in TRAMP mice. Cancer Prev Res (Phila). 3:1284-91.
39. Singh SV, et al. (2008) Garlic constituent diallyl trisulfide prevents development of poorly differentiated prostate cancer and pulmonary metastasis multiplicity in TRAMP mice. Cancer Res. 68:9503-11.
40. Li L, et al. (2005) The emerging role of the PI3-KAkt pathway in prostate cancer progression. Prostate Cancer Prostatic Dis. 8:108-18.
41. El Touny LH, Banerjee PP. (2007) Akt GSK-3 pathway as a target in genistein-induced inhibition of TRAMP prostate cancer progression toward a poorly differentiated phenotype. Carcinogenesis. 28:1710-7.
42. Ciarlo M, et al. (2012) Regulation of neuroendocrine differentiation by AKT/hnRNPK/AR/beta-catenin signaling in prostate cancer cells. Int. J. Cancer. 131:582-90.
43. Nelson WG, De Marzo AM, Isaacs WB. (2003) Prostate cancer. N Engl. J. Med. 349:366-81.
44. Senapati S, et al. (2010) Overexpression of macrophage inhibitory cytokine-1 induces metastasis of human prostate cancer cells through the FAKRhoA signaling pathway. Oncogene. 29:1293-302.
45. Slack JK, et al. (2001) Alterations in the focal adhesion kinase/Src signal transduction pathway correlate with increased migratory capacity of prostate carcinoma cells. Oncogene. 20:1152-63.
46. Schmidmaier R, Baumann P. (2008) ANTIADHESION evolves to a promising therapeutic concept in oncology. Curr. Med. Chem. 15:978-90.
47. Trachootham D, et al. (2006) Selective killing of oncogenically transformed cells through a ROSmediated mechanism by beta-phenylethyl isothiocyanate. Cancer Cell. 10:241-52.
48. Hussong R, et al. (2005) A safety study of oral xanthohumol administration and its influence on fertility in Sprague Dawley rats. Mol. Nutr. Food Res. 49:861-7.
49. Gerhauser C. (2005) Beer constituents as potential cancer chemopreventive agents. Eur. J. Cancer. 41:1941-54.
50. Lechertier T, Hodivala-Dilke K. (2012) Focal adhesion kinase and tumour angiogenesis. J. Pathol. 226:404-12.
51. Yatani R, et al. (1982) Geographic pathology of latent prostatic carcinoma. Int. J. Cancer. 29:611-6.
52. Shukla S, et al. (2007) Blockade of beta-catenin signaling by plant flavonoid apigenin suppresses prostate carcinogenesis in TRAMP mice. Cancer Res. 67:6925-35.